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ston, Illinois, USA; and 5Department of Nephrology, University of Chicago, Chicago, Illinois, USAIntroduction: Chronic kidney disease (CKD) is known to be associated with reduced renal blood ﬂow.
However, data in humans are limited to date.
Methods: In this study, noninvasive arterial spin labeling magnetic resonance imaging data were acquired
in 33 patients with diabetes and stage 3 CKD as well as in 30 healthy controls.
Results: A signiﬁcantly lower renal blood ﬂow in both the cortex (108.4  36.4 vs. 207.3  41.8; P < 0.001,
d ¼ 2.52) and medulla (23.2  8.9 vs. 42.6  15.8; P < 0.001, d ¼ 1.5) was observed. Both cortical (r ¼ 0.67,
P < 0.001) and medullary (r ¼ 0.62, P < 0.001) blood ﬂow were correlated with estimated glomerular
ﬁltration rate, and cortical blood ﬂow was found to be confounded by age and body mass index. However,
in a subset of subjects who were matched for age and body mass index (n ¼ 6), the differences between
CKD patients and control subjects remained signiﬁcant in both the cortex (107.4  42.8 vs. 187.51  20.44;
P ¼ 0.002) and medulla (15.43  8.43 vs. 39.18  11.13; P ¼ 0.002). A threshold value to separate
healthy controls and CKD patients was estimated to be a cortical blood ﬂow of 142.9 and a medullary blood
ﬂow of 24.1.
Discussion: These results support the use of arterial spin labeling in the evaluation of renal blood ﬂow in
patients with a moderate level of CKD. Whether these measurements can identify patients at risk for
progressive CKD requires further longitudinal follow-up.
Kidney Int Rep (2017) 2, 36–43; http://dx.doi.org/10.1016/j.ekir.2016.09.003
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).R ecent advances in understanding the pathophysi-ology of chronic kidney disease (CKD) suggest that
the pathogenic mechanisms causing progressive renal
destruction converge on a common tubulo-interstitial
pathway characterized by tubular atrophy and
hypoxia, peritubular capillary injury, and interstitial
ﬁbrosis, ﬁnally leading to irreversible scarring.1,2 Prior
studies have evaluated the use of blood oxygenation
leveldependent and diffusion magnetic resonance im-
aging (MRI) to monitor differences in relative levels of
hypoxia and interstitial ﬁbrosis in patients with
CKD.3,4 The key advantage of these 2 methods is that
they are both endogenous contrast mechanisms andspondence: Pottumarthi V. Prasad, Department of Radiology,
Shore University Health System, 2650 Ridge Avenue,
ton, IL 60035, USA. E-mail: pprasad@northshore.org
ved 9 May 2016; revised 17 August 2016; accepted 6
mber 2016; published online 13 September 2016require no administration of exogenous contrast media,
which are contraindicated in subjects with compro-
mised renal function.5 The ability to include an endog-
enous method to evaluate renal perfusion would be of
great interest in developing a comprehensive func-
tional protocol to understand the natural progression
of CKD. Currently, there are not many data on renal
blood ﬂow or perfusion in patients with CKD.
Arterial spin labeling (ASL) MRI uses endogenous
water as a tracer and is widely used in the brain.6 Even
though feasibility has been demonstrated in the kid-
neys,7,8 a key challenge for ASL MRI is the inherently
limited signal-to-noise ratio (SNR) necessitating
repeated measurements to allow data averaging.9 This
is a major hurdle in the abdomen, because breath
holding limits the number of averages that can be
performed. Although the feasibility of renal perfusion
MRI with ASL has been demonstrated using breath-
hold acquisitions in healthy subjects,7 it is moreKidney International Reports (2017) 2, 36–43
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perfusion. Coached breathing10–12 or navigator gated
acquisitions13 have been used. Navigator gating in-
volves additional data acquisition to estimate the mo-
tion that can be used to decide whether to accept or
reject the measurement. In prospective gating, this
decision is made in real time. In retrospective gating, a
ﬁxed number of data acquisitions are made, and accept
or reject decisions are made retrospectively. In this
study, we have evaluated renal perfusion using a
retrospectively navigator gated ASL MRI sequence13 in
a sufﬁciently large number of subjects with chronic




All procedures were performed with approval from the
institutional review board and written subject consent
prior to enrollment. MRI data were acquired in a group
of diabetic patients with stage 3 CKD (n ¼ 33) and
healthy subjects (n ¼ 30) with no known renal disease.
Subjects were instructed not to take nonsteroidal anti-
inﬂammatory drugs for 3 days and angiotensin-
converting enzyme inhibitors/angiotensin receptor
blockers 1 day prior to MRI. Both groups were
instructed to fast after midnight on the day of the MRI
and to take one-half the dose of insulin if applicable.
Blood was drawn for estimated glomerular ﬁltration
rate (eGFR) calculation either on the day of the scan for
healthy subjects or during the screening visit prior to
the MRI scan for patients. The Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation was
used for eGFR calculation.14 Twenty-four-hour urine
samples were collected within a few days after MRI in
most of the patients with CKD (28/33) for analysis of
urine creatinine and protein excretion.
Because data were acquired in the fasted status, in 8
of the healthy subjects (30.6  11.1 years), we also
evaluated any potential effect of hydration on ASL-
derived perfusion measurement on a separate day. For
these studies, subjects followed the same preparation as
above. Urine-speciﬁc gravity was used to document the
subject’s hydration status. Urine samples were ac-
quired prior to the baseline scan, and 1 sample
following each MRI acquisition after water loading.
Following the ASL baseline scan, subjects drank water
based on their body weight (20 ml/kg) within 15 mi-
nutes. After water loading, ASL MRI data were ac-
quired 2 times.
MRI Acquisition Methods
All the studies were performed on a 3.0T MRI system
(MAGNETOM Verio, Siemens Healthcare, Erlangen,Kidney International Reports (2017) 2, 36–43Germany) equipped with high-performance gradient
coils (45 mT/m maximum gradient strength, 200 mT/m/
ms slew rate). The body coil was used as the trans-
mitter, and the combination of spine and body array
coils was used as the receiver. Subjects were positioned
feet ﬁrst and supine.
The renal perfusion measurement was performed
using the 2-dimensional navigator-gated FAIR True-
FISP sequence.13 A 10.24-millisecond adiabatic fre-
quency offset corrected inversion (FOCI) pulse (m ¼ 6,
b ¼ 1078) was used for selective inversion.15 The scan
prescription included the following: (i) deﬁning the
imaging slice (thickness ¼ 8 mm) position in an oblique
coronal orientation to match the longitudinal axis of
both kidneys; (ii) positioning a slice selective inversion
band (thickness ¼ 30 mm) over the imaging slice, with
care taken to avoid intersection with major arteries; and
(iii) choosing the slice position for the navigator in the
coronal plane. To allow sufﬁcient labeled blood to
perfuse into the tissue, an inversion pulse delay time (TI)
of 1.5 seconds for healthy controls or 2.0 seconds for
patients was used.13 The imaging readout used a true fast
imaging with steady precession sequence (TR/TE¼ 4.0/
2.02 milliseconds; FA ¼ 60; ﬁeld of view ¼ 360400
mm; matrix ¼ 128  128; BW ¼ 651 Hz/pixel). The 2-
dimensional navigator acquisition was performed
immediately following the imaging readout using a fast
low angle shot (FLASH) readout (TR/TE ¼ 2.2/1.2 ms;
FA ¼ 5; ﬁeld of view¼ 400 400 mm2; matrix¼ 96 
96; BW ¼ 1000 Hz/pixel; generalized autocalibrating
partially parallel acquisitions [GRAPPA] factor ¼ 2).
The acquisition efﬁciency of this 2-dimensional
navigator in a previous study was about 35% (range,
26%39%) in patients and 50% (range, 35%65%) in
healthy subjects, depending on the respiratory
pattern.13 To maintain protocol consistency, we took a
conservative approach and acquired 50 control/label
pairs of perfusionweighted images with a total scan time
of 5 minutes in healthy subjects and 100 control/label
pairs of perfusionweighted images with a total scan time
of 10 minutes during free breathing in subjects with
CKD. A proton densityweighted (M0) image was ac-
quired using an identical True-FISP readout with a pulse
repetition time of 10 seconds and no inversion pulse.
MRI Analysis Methods
ASL maps were reconstructed using a MATLAB
(MathWorks, Natick, MA) based custom suite of soft-
ware.13 Navigator data was used to estimate the
translational motion in the coronal plane. Only images
where the diaphragm position was within the accep-
tance window (8-mm width) were selected for the
perfusion calculation. This processing scheme leads to a
variation in the ﬁnal number of selected control and37






CKD 33 18:15 11:22:0 ACEI/ARB (n ¼ 23)
Control 30 6:24 10:16:4 n/a
AA, African American; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; C, Caucasian; CKD, chronic kidney disease; n/a, not applicable; O, other.
CLINICAL RESEARCH L-P Li et al.: Renal Blood Flow in Chronic Kidney Disease by MRIlabel images for each subject. Selected images were
further realigned using the FMRIB’s Linear Image
Registration Tool (FLIRT, FMRIB, Oxford, UK).16 The
ﬁrst image of each sequence was used as the reference,
and the remaining images were aligned with it. Control
and label images were then separately averaged to yield
a single control image and a single label image. The
ﬁnal perfusion weighted image was computed by
subtracting the averaged control from the averaged
label image. Quantitative renal blood ﬂow was calcu-










where f is the perfusion rate (in the unit of ml/100 g/min), l
is the blood–tissue–water partition coefﬁcient, which was
assumed to be 80 ml/100 g,18 a is the inversion efﬁciency,
which was assumed to be 0.95, DM(TI) is the perfusion
weighted image, and M0 is the equilibrium magnetization of
the tissue (proton density). The T1 value of 1.15 seconds for
the renal cortex19 is assumed to be the T1 of the blood.
Regions of interest (ROIs) were manually deﬁned in
the cortex and medulla on ASL maps to calculate blood
ﬂow using a custom image processing toolbox written
in Python (Python Software Foundation, Wilmington,
DE).20,21 ROIs were deﬁned in the cortex and medulla
for both the left and right kidneys. Tumors and cysts
were excluded from the ROIs. The cortical ROI was
deﬁned as 1 large ROI (>500 voxels) encompassing the
vast majority of the cortex. Medullary ROIs were
drawn using a freehand tool and typically consisted of
less than 100 voxels. After all the ROIs were deﬁned for
both kidneys in each subject, the mean value of each
region was computed to obtain 1 representative value
per subject per region (cortex and medulla).
Statistical Methods
A 2-sample t test or Wilcoxon rank sum test (if
normality in distribution was not observed) was used
to compare the various MRI-derived parameters, along
with age and eGFR, between the CKD and control
groups. We included Cohen’s d as the measure of the
magnitude of difference between groups. Cohen’s
d represents the effect size, and in this study we
recognize 3 levels: small, medium, and large. These
levels correspond to d values greater than or equal to
0.2, 0.5, and 0.8, respectively.22
Spearman correlation coefﬁcients were calculated
among the following variables: cortical blood ﬂow
(Cor_BF), medullary blood ﬂow (Med_BF), eGFR, age,
and body mass index (BMI). P values are reported for
all statistical tests. Linear regression was used to
explore the pairwise relationship between Cor_BF,38Med_BF, and eGFR. Multiple linear regressions were
used to explore the pairwise relationship accounting
for any potential confounding effect of age, gender,
race, or BMI where appropriate. The confounder was
retained in the model if it changed the regression co-
efﬁcient of eGFR more than 15%. Parameter estimate,
SE, and P values were reported for the regression
analyses.
Aside from the regression analysis, the confounding
effects (if any) in the above-mentioned analysis were
removed by conducting a 1:1 age, gender, race, or BMI
matching between the CKD and control groups. The
propensity score matching method used a greedy 8-to-1
matching algorithm for identifying matched pairs.
The Cor_BF and Med_BF readings from the 2 groups
were used to assess whether ASL measurement could
be used to discriminate CKD from healthy subjects. The
optimal thresholds for Cor_BF and Med_BF were
determined by conducting a receiver operating char-
acteristic (ROC) analysis using each measure (Cor_BF
and Med_BF) alone as a continuous variable to distin-
guish abnormal perfusion in CKD from normal subjects.
Areas under the curve were estimated with a 95%
conﬁdence interval. Sensitivity and speciﬁcity for the
optimal threshold for each measure were determined
by the Youden Index.
Repeated-measures analysis of variance was used to
compare the changes from baseline for Cor_BF and
speciﬁc gravity for water-loading results. Multiple
comparisons were adjusted.
All of the statistical analyses were carried out in SAS
9.3 (SAS Institute, Cary, NC), and a P value of <0.05
was regarded as statistically signiﬁcant.
RESULTS
A total of 33 patients with CKD and 30 control subjects
participated in our study (Table 1). The median eGFR
and 24-hour urine protein excretion in patients was
46.7 ml/min/1.73 m2 and 0.18 g, respectively (Table 2).
However, most of the subjects with CKD were taking
angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers. There were signiﬁcantly
higher proportion of female patients in the CKD group
than in the healthy control group (54.6% vs. 20%,
P ¼ 0.0048). The 2 groups had similar proportions of
African American to white subjects.Kidney International Reports (2017) 2, 36–43
Table 2. Interquartile range of age, BMI, eGFR, and urine protein
Parameter Group n Mean SD Median Q1 (25%) Q3 (75%)
Age CKD 33 68.1 9.0 69.4 61.0 74.8
Control 30 42.0 18.1 42.7 22.5 55.0
BMI (kg/m2) CKD 33 31.8 6.3 30.1 27.3 35.8
Control 30 24.5 3.3 23.3 22.8 26.4
eGFR (m/min/1.73 m2) CKD 33 50.0 13.9 46.7 39.3 62.9
Control 30 100.7 17.7 101.9 87.0 111.6
Urine protein (g) CKD 28 1.86 4.6 0.175 0 1.045
Control n/a n/a n/a n/a n/a n/a
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; n/a ¼ not available;
Q, quartile.
L-P Li et al.: Renal Blood Flow in Chronic Kidney Disease by MRI CLINICAL RESEARCHFigure 1 shows representative renal perfusion maps
from a healthy subject and a subject with CKD. The
color bar shows the blood ﬂow in units of milliliters per
minute per 100 g. One can appreciate the lower renal
blood ﬂow in the subject with CKD compared to the
healthy subject.
Table 3 summarizes variables in this study based on
groups. All variables age, eGFR, BMI, Cor_BF, and
Med_BF were signiﬁcantly different between CKD and
controls (P values < 0.0001, d values > 1.4 [range,
1.43.19]). In addition, there was no difference be-
tween left and right kidneys in both the CKD and
control groups (data not shown).
Table 4 shows all pairwise correlation among the
variables age, eGFR, Cor_BF, Med_BF, and BMI. Because
age, Cor_BF, and Med_BF were correlated with eGFR, aFigure 1. Representative images obtained with retrospective 2-dimensiona
the ASL perfusion map from a healthy control subject, and on the right is on
level settings were the same for both. Note the reduced blood ﬂow in th
Kidney International Reports (2017) 2, 36–43regression analysis was conducted to test for potential
confounding effect of age, race, gender, and BMI on the
relationship between blood ﬂow with eGFR. Table 5
shows the results of the linear regression for both
Cor_BF and Med_BF against eGFR. Age and BMI were
found to be confounding factors by multiple linear
regression analysis for Cor_BF but not Med_BF (Table 6)
based on changes in the regression coefﬁcient of BF
versus eGFR of more than 15%. The results of the
ANOVA are in the Supplementary Tables. Table 7 shows
the comparison between CKD and healthy controls for
age- and BMI-matched pairs of subjects. All 3 parameters
eGFR, Cor_BF, and Med_BF showed signiﬁcant differ-
ences between CKD and healthy control subjects, even
though the sample size was small (n ¼ 6).
The optimal threshold to separate CKD and healthy
for Cor_BF was estimated to be 142.9 (Youden Index ¼
0.85) and Med_BF was 24.1 (Youden Index¼ 0.64). The
sensitivity and speciﬁcity for this threshold were
84.85% and 100.00% for Cor_BF and 60.61% and
100.00% for Med_BF. The accuracy was estimated by
the area under the ROC curve. The area under the ROC
curve for Cor_BF was 0.98, which is rated as excellent,
and for Med_BF was 0.88, which is rated as good.
Even though speciﬁc gravity showed signiﬁcant
reduction after water loading compared to baseline
(1.00  0.01 vs. 1.03  0.0, P < 0.0001), there was no
difference in Cor_BF (208.1  33.4 vs. 193.9  26.7,l navigator gated arterial spin labeling (ASL) sequence. On the left is
e from a subject with chronic kidney disease (CKD). The window and
e subject with CKD compared to the control subject.
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Table 5. Multiple linear regression analysis with eGFR as
independent and BF as dependent variable
Region Parameter Estimate SE P value
Cor_BF Intercept 54.70 14.61 0.0004
Slope (eGFR) 1.33 0.18 <0.0001
Med_BF Intercept 10.42 3.87 0.0092
Slope (eGFR) 0.28 0.05 <0.0001
BF, blood ﬂow; Cor_BF, cortical blood ﬂow; eGFR, estimated glomerular ﬁltration rate;
Med_BF, medullary blood ﬂow.
Table 3. Characteristics of CKD and healthy control subjects at
baseline
Parameter Health status n Mean SD P value d Value
Age CKD 33 68.1 9.0 <0.001 1.83
Healthy 30 42.0 18.1
BMI CKD 33 31.7 6.3 <0.001 1.4
Healthy 30 24.5 3.3
eGFR CKD 33 50.0 13.9 <0.001 3.19
Healthy 30 100.7 17.7
Cor_BF CKD 33 108.4 36.4 <0.001 2.52
Healthy 30 207.3 41.8
Med_BF CKD 33 23.2 8.9 <0.001 1.5
Healthy 26 42.6 15.8
BMI, body mass index; CKD, chronic kidney disease; Cor_BF, cortical blood ﬂow; eGFR,
estimated glomerular ﬁltration rate; Med_BF, medullary blood ﬂow.
CLINICAL RESEARCH L-P Li et al.: Renal Blood Flow in Chronic Kidney Disease by MRIP ¼ 0.34) and Med_BF (90.6  32.2 vs. 91.9  18.4,
P ¼ 0.99), suggesting that hydration may not have a
signiﬁcant inﬂuence on ASL-derived renal perfusion
estimates.
DISCUSSION
Blood ﬂow to the kidneys is thought to be reduced
with progression of CKD.2 The conventional method for
measuring renal blood ﬂow is the para-aminohippurate
clearance method.23 This is invasive and time
consuming and hence only used for research purposes.
Contrast-enhanced MRI24 and computed tomography25
methods can be used to measure renal blood ﬂow;
however, they are contraindicated in patients with
CKD.5 Nuclear medicinebased methods are available
to estimate renal blood ﬂow26 but are not widely used
in the clinic. Overall, there are very few data available
on renal blood ﬂow in subjects with CKD. A recent
study used phase contrast MRI to measure blood ﬂow
within renal arteries in subjects with CKD, and found
that the ﬂow was reduced by about 28% and measured
GFR was reduced by 37%.27
Prior studies have demonstrated the feasibility of
acquiring ASL perfusion MRI measurements in the kid-
neys7,8 andpreliminarydata showeddifferences between
subjects with CKD and healthy controls with smallTable 4. Summary of Spearman correlation coefﬁcients (r)
Age eGFR Cor_BF Med_BF BMI
Age 1 0.62 0.58 0.39 0.47
P value <0.0001 <0.0001 0.0028 <0.0001
eGFR 1 0.67 0.62 0.58
P value <0.0001 <0.0001 <0.0001
Cor_BF 1 0.70 0.55




BMI, body mass index; Cor_BF, cortical blood ﬂow; eGFR, estimated glomerular ﬁltration
rate; Med_BF, medullary blood ﬂow.
40numbers of subjects.13,28 Although only a few studies
evaluating ASLMRImeasurements have been performed
to date, the technique has been shown to be reproduc-
ible.29,30 Furthermore, ASL MRIderived perfusion
estimates correlated well with para-aminohippuric acid
measurements and were able to discriminate pharmaco-
logic changes in renal plasma ﬂow.31 The comparison of
the ASL technique with a microsphere method in an
animalmodel has shown that cortical perfusionmeasured
with ASL correlated with microspheres in the expected
physiologic range.32 In a group of 98 transplant re-
cipients, ASLMRI identiﬁed reduced cortical blood ﬂow
in subjects with reduced renal function (eGFR # 30 ml/
min/1.73 m2) compared to those with good-to-moderate
renal function (eGFR > 30 ml/min/1.73 m2).33
Consistent with previously reported data, our data
show a signiﬁcant reduction in cortical and medullary
blood ﬂow in subjects with CKD compared to healthy
controls in a moderately large number of subjects. We
further observed a signiﬁcant correlation of renal blood
ﬂow with eGFR. Cortical blood ﬂow and eGFR were
reduced by w50% in subjects with CKD compared to
controls. Multiple linear regression analysis found age
and BMI to be confounders for cortical blood ﬂow.
However, within the age- and BMI-matched group, the
difference in eGFR and renal blood ﬂow between CKD
still remained signiﬁcant.
Proteinuria is a common clinical signature observed
in patients with diabetic nephropathy. In our study,
the median value of 24-hour urine protein was rela-
tively low (0.175 g), probably due to the use ofTable 6. Multiple linear regression analysis with eGFR as
independent and BF as dependent variable with adjustment for age
and BMI
Region Parameter Estimate SE P value
Cortex Intercept 143.49 50.01 0.0057
Slope (eGFR) 0.99 0.26 0.0004
Slope (age) 0.38 0.39 0.345
Slope (BMI) 1.50 1.04 0.1561
Medulla Intercept 15.11 13.50 0.2682
Slope (eGFR) 0.27 0.07 0.0004
Slope (age) 0.02 0.10 0.8469
Slope (BMI) 0.18 0.28 0.5307
BF, blood ﬂow; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate.
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Table 7. Summary of age- and BMI-matched groups
Parameter Health Status n Mean SD P value
Age CKD 6 63.22 7.15 0.6884
Healthy 6 65.07 9.86
BMI CKD 6 25.89 3.34 0.6408
Healthy 6 25.02 2.93
eGFR CKD 6 45.73 11.72 <0.0001
Healthy 6 92.76 11.36
Cor_BF CKD 6 107.4 42.8 0.002
Healthy 6 187.51 20.44
Med_BF CKD 6 15.43 8.43 0.0019
Healthy 6 39.18 11.13
BMI, body mass index; CKD, chronic kidney disease; Cor_BF, cortical blood ﬂow; eGFR,
estimated glomerular ﬁltration rate; Med_BF, medullary blood ﬂow.
L-P Li et al.: Renal Blood Flow in Chronic Kidney Disease by MRI CLINICAL RESEARCHangiotensin-converting enzyme inhibitors and/or
angiotensin receptor blockers.
Renal blood ﬂow in CKD patients is about one-half of
that in healthy controls in both the renal cortex
(108.4  36.4 vs. 207.3  41.8; P < 0.001, d ¼ 2.52)
and medulla (23.2  8.9 vs. 42.6  15.8; P < 0.001,
d ¼ 1.5). Because we performed studies following an
overnight fast, we wanted to determine whether hy-
dration status would have any signiﬁcant inﬂuence on
renal blood ﬂow as evaluated by ASL. In a small sub-
study, we looked at the effect of water loading in fasted
healthy subjects on ASL measurements. Although the
urine speciﬁc gravity changed signiﬁcantly after water
loading, the renal perfusion estimates did not change.
This suggests that ASL MRIbased perfusion estimates
may not be inﬂuenced by hydration status within
normal limits.
There are a few limitations to this study. The control
group was not age, gender, and BMI matched with the
CKD group. Even though age and BMI were found to be
confounding factors in the relationship between cortical
blood ﬂow and eGFR, when identifying a subgroupwith
matched age and BMI, both cortical andmedullary blood
ﬂow were signiﬁcantly lower in subjects with CKD
compared to the control group. The ASL MRI protocol
used here required 5 to 10 minutes for data acquisition.
Even though these are during free breathing, they could
be considered to be long, especially for a single slice
acquisition. For this preliminary study, we were con-
servative and acquired more data than necessary. In a
small number of subjects with CKD (n ¼ 6), data using
only one-half the number of acquired images yielded
comparable perfusion estimates (data not shown). These
preliminary data could be used to optimize the total
acquisition time for future use. Absolute quantiﬁcation
of renal blood ﬂow with the present implementation of
ASL has not yet been validated, for example, against
microspheres. The current values for cortical perfusion
(w200ml/min/100 g) are lower than in our ownprevious
report (w260 ml/min/100 g). The key differenceKidney International Reports (2017) 2, 36–43between these 2 studies is that the subjects in the current
study fasted before the scan. In fact, that was the moti-
vation to study the potential effects of water loading on
renal perfusion. We may need future studies to verify
the effects of fasting. Even though a previous study has
validated ASL estimated cortical perfusion against mi-
crospheres,23 no such validation is available for medul-
lary blood ﬂow estimates. ASL is inherently limited in
sensitivity to low ﬂow. However, the primary interest in
routine use demands precision rather than accuracy. A
recent report suggests a high degree of reproducibility of
renal ASL MRI when repeated after 2 weeks.29 In this
study, we used longer TI for patients, assuming slower
circulation compared to that of controls.13,34 Although
this is not ideal, it should not unduly inﬂuence the
estimatedﬂow, as the quantitation takes TI in to account.
In a healthy volunteer, the ﬂow estimates were relatively
stable for a range of TI values between 1 and 2 seconds
(146.4  15.9 ml/min/100 g). The values for TI outside
this range were considerably lower. Future studies may
have to include multiple TIs to estimate both average
transit times and transit timecorrected blood ﬂow es-
timates, as suggested by a recent report.34
In conclusion, ASL-derived renal perfusion values
were signiﬁcantly lower in subjects with CKD and
correlated with eGFR. Both cortical blood ﬂow and
eGFR were reduced about 50% in the CKD group
compared to controls. Overall, the data presented here,
along with other recent studies support the feasibility
of using ASL perfusion MRI in the evaluation of CKD to
identify early markers of progression. The signiﬁcant
and large difference between CKD and healthy subjects
makes this ASL technique a potential tool to document
the change in perfusion in longitudinal studies. Com-
bined with blood oxygenation leveldependent MRI
to evaluate relative renal hypoxia and diffusion MRI to
evaluate ﬁbrosis,3,4 a comprehensive and noninvasive
suite of tools may now be available for evaluating the
chronic hypoxia hypothesis.2 The differences observed
here between CKD and control groups are probably
smaller compared to differences between progressive
CKD patients and control groups, as it has been re-
ported that only one-third of patients with diabetes
may show progressive decline in renal function.35
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